ValueAct’s Valeant Problem

July 21, 2016  


Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?

By Michelle Celarier ValueAct Capital Management’s Jeffrey Ubben has carefully cultivated a reputation as a good-guy activist who works with management to get results — a reputation that was built in part on his tremendous success with Canadian drugmaker Valeant …

Subscribe

Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.

Subscribe now

Free trial

Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.

Free Trial



 

Planning for a high-income year due to 457A income? Download this short paper to find out more about the opportunity to reduce tax liability and have significant charitable impact..

Click here for more details.


Latest Poll

How will hedge funds finish 2017?

 - 71%
 - 21%
 - 7%

View previous results